title: Blepharitis induced by epidermal growth factor receptor-targeting therapy.
authors.affiliation: Department of Hematology/Oncology, Paul Brousse Hospital, Villejuif, France. ayhan.ulusakarya@pbr.ap-hop-paris.fr
authors.forename: Ayhan
authors.initials: A
authors.lastname: Ulusakarya
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Gumus
authors.forename: Béatrice
authors.initials: B
authors.lastname: Delmas-Marsalet
authors.forename: David
authors.initials: D
authors.lastname: Machover
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001762:Blepharitis / Q000139:chemically induced*; D000068818:Cetuximab; D003110:Colonic Neoplasms / Q000188:drug therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors; D000068818:Cetuximab